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A B S T R A C T
The aim of this study was to investigate the effect of backing films on transdermal deliv-
ery of cyclobenzaprine patch. Different backing films were chosen to prepare the
cyclobenzaprine transdermal patch. The cumulative amount of cyclobenzaprine released
from different patches was evaluated in vitro. To investigate the interaction between
cyclobenzaprine and backing films, the partitioning experiments and attenuated total re-
flectance Fourier transform infrared (ATR-FTIR) spectroscopy were performed.The cumulative
amount of cyclobenzaprine released from the patch with Cotran™ 9700 as backing film was
less than that of other patches with different backing films. Furthermore, the cumulative
amount of cyclobenzaprine released from the patch with Cotran™ 9700 as backing film de-
creased significantly after 7 d storage at room condition.The partitioning experiments indicated
a strong adsorption of cyclobenzaprine onto the Cotran™ 9700, which could explain the de-
crease of cumulative amount of cyclobenzaprine released from the patch with Cotran™ 9700
as backing film.According to the ATR-FTIR results, there was no interaction between Cotran™
9700 and cyclobenzaprine. The effect of backing films on the release behavior of
cyclobenzaprine transdermal patch was attributed to the adsorption of cyclobenzaprine onto
the Cotran™ 9700.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This









Cyclobenzaprine (CBZ), a centrally acting muscle relaxant, has
an established efficacy and safety profile, with more than 30
years of practical application in the clinical low back pain setting
[1,2]. Tablets and capsules were the only two dosage forms of
CBZ available on the market [3]. The clinical application was
limited by its compliance and side effect, such as sedation and
somnolence. It is reported that the side effects were associ-
ated with high peak plasma concentration [4], which meant
that maintaining a stable plasma concentration would result
in a better control of side effect. It was known that transder-
mal delivery could bemore possible to maintain a stable plasma
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concentration than tablets. Therefore, transdermal patch con-
taining CBZ may decrease the side effect and improve the
compliance greatly.
Backing film is an important component of the transder-
mal patch as it could provide an occlusive environment of skin.
However, there are few reports about the effect of backing film
on the formulation screening of transdermal patch.There was
only one study that reported the interaction between the
backing film and drug [5]. The aim of this study was to make
sure if the backing film had an effect on the release of CBZ from
a transdermal patch and if there was an interaction between
the CBZ and backing film. In the study, different backing films
consisted of different materials, chosen to evaluate the effects
of the release of CBZ from the transdermal patch by release
experiment in vitro, and the interaction between CBZ and
backing film was investigated by partitioning experiment and
ATR-FTIR.
2. Materials and methods
2.1. Materials
Cyclobenzaprine hydrochloride (CBZ HCl) was purchased from
Far Top Pharmaceutical Co., Ltd. (Nanjing, China); DURO-
TAK®87–4098 was purchased from Henkel (Holthausen,
Germany); Release liner ScotchPak®9744, backing films Cotran™
9700, Cotran™ 9718, Scotchpak™ 9733, Scotchpak™ 9723,
Scotchpak™ HB-P-69731 were bought from 3M company (3M,
USA). All other chemicals were of analytical grade.
2.2. The preparation of CBZ base
CBZ base was prepared in our laboratory as follows: CBZ HCl
solution (50 mg/ml) was adjusted to pH 12 using NaOH solu-
tion (40 mg/ml), then, the CBZ base was extracted into ethyl
acetate. The ethyl acetate was removed using a rotary evapo-
rator.The purity of the obtained CBZ base was over 99.9% which
was measured in the area normalization method by HPLC.
2.3. Preparation of patches
The drug-in-adhesive patches were prepared by the solvent
evaporation technique [6]. CBZ and pressure-sensitive adhe-
sive were dissolved in a minimum amount of ethyl acetate and
mixed thoroughly with a magnetic bar for 2 h until it became
homogeneous.The mixture was then cast onto a release liner.
After that, the film was placed at room temperature for 15 min
and then put into an oven set at 50 °C for 5 min. The solvent
was removed and the dry filmwas coated with different backing
films.The control patch in the release experiment was coated
with the release layer as backing film.
2.4. In vitro release experiments
The two-chamber side-by-side glass diffusion cells
(volume = 4.0 ml and effective diffusion area = 0.95 cm2) were
used in the release experiment. The test patch was pasted on
the cellophane membrane and the cellophane membrane was
mounted onto the diffusion cells.The cells were filled with 4 ml
PBS and the solution was stirred at about 600 rpm and main-
tained at 32 ± 0.5 °C using a thermostatic water pump. At pre-
determined time interval, 2 ml samples were withdrawn and
2 ml fresh PBS was added.The samples were analyzed by HPLC
method.
2.5. Partition of CBZ between backing film and medium
Backing films Cotran™ 9700, Cotran™ 9718, Scotchpak™ 9733,
Scotchpak™ 9723, Scotchpak™ HB-P-69731 were weighed as
1 cm2 pieces and placed in a 4 ml solution of CBZ (20 μg/ml)
in a glass test tube, with 1:49 (v/v) of methanol and water as
solvent. The test tubes were shaken for 24 h to reach equilib-
rium at 32 °C and the solution was analyzed by HPLC for drug
content after equilibrium. Partition coefficients were calcu-
lated from CBZ concentration in the solution before and after
equilibrium by the following equation: K = (C0 − C)/C.
C0 and C represent drug concentration in the CBZ solution
before and after partitioning, respectively.
2.6. ATR-FTIR measurements
The backing film was cut into 1 × 1 cm square pieces and was
divided into two groups. In one group, these backing films were
treated as described in partition study. In the other group, the
backing films were incubated in 4 ml of the blank solution
(methanol: water, 1:49, v/v) for 24 h as control.Then, the backing
films were dried at 40 °C for 2 h. The spectral measurements
were performed with a Nicolet NEXUS 470 Fourier Transform
Infrared Spectrometer (Thermo Nicolet, USA) equipped with
an attenuated total reflectance (ATR) attachment.
2.7. Quantitative analysis
CBZ concentration was assayed using a Hitachi HPLC system
(pump L-2130, UV-Vis detector L-2420, autosampler L-2200,
T2000L workstation) equipped with a Diamonsil ODS (5 μm,
200*4.6 mm) at 290 nm as reported previously [7]. The mobile
phase consisted ofmethanol/water/formic acid (300:200:1, v/v/v),
and the flow rate was set at 1 ml/min.
2.8. Data analysis
Results of each experiment are presented as the mean ± SD of
three or four experiments. Statistical analysis was conducted
by using Student’s t-test. A difference between data was con-
sidered significant when P < 0.05.
3. Results and discussion
3.1. In vitro release experiments
The process of drug traveling from patch to skin can be divided
into two steps: drug release from the patch and then perme-
ation through the skin [8]. As we have known, stratum corneum
was the main barrier for transdermal drug delivery and it was
not in touch with the backing film directly. So the effect of
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backing film on transdermal drug delivery was mainly
dependent on the release process. In vitro release experiment
would be more suitable compared to permeation experiment
in investigating the effect of backing films on transdermal patch.
The CBZ transdermal patches with different backing films were
prepared and each patch was divided into 3 groups.The release
experiment was performed immediately for the patches in
group 1. For the patches in groups 2 and 3, these were stored
for 7 d and 15 d before the release experiment, respectively. As
shown in Fig. 1, the cumulative release amount of patch pre-
pared with Cotran™ 9700 was less than that of the control patch
and the difference between them was statistically significant
(P < 0.05).The cumulative release amount of control patch was
similar to that of the patches with other backing films. Fur-
thermore, the release amount of the patch prepared with
Cotran™ 9700 further decreased after 7 d storage at room con-
dition. There was no significant difference in the cumulative
release amount of other patches after storage. The only dif-
ference between the control patch and the patch prepared with
Cotran™ 9700 was the backing film. This indicated that the
backing film may be responsible for the difference in cumu-
lative release amount of the two patches. And in other words,
Cotran™ 9700 had some effects on CBZ release from trans-
dermal patch.
3.2. Partition of CBZ between backing film and medium
The results of the release experiment suggested that there may
be some interaction between CBZ and backing films.To compare
the affinity between the CBZ and different backing films, the
partitioning experiments were performed. Partitioning experi-
ment was a time-saving, simple and convenient method to
confirm the affinity between CBZ and backing film, which was
often used in the determination of drug solubility in the PSA
matrix [8,9].The partition coefficient of CBZ between the same
medium and different backing film was used to compare the
affinity between CBZ and different backing films. The higher
partition coefficient suggested the stronger affinity between
CBZ and backing film.As shown in Table 1, it was inferred that
the affinity between CBZ and Cotran™ 9700 was significantly
stronger than other groups. And the results agreed with the
results of release experiment. The affinity between CBZ and
Cotran™ 9700 might be the reason for the less cumulative
release amount of the patch prepared with Cotran™ 9700. It
can be inferred that it took time to reach equilibrium of ad-
sorption. And this may be the reason for the decreased release
profiles of the patch after storage.
3.3. ATR-FTIR measurements
The results of the release experiments and partitioning ex-
periments both indicated the potential interaction between CBZ
and Cotran™ 9700. The results were in accordance with the
results of experiments done by Liu Nannan [5]. In her study,
it was concluded that intermolecular hydrogen bonds formed
between Cotran™ 9700 and the drug. As known, ATR-FTIR was
a classical spectroscopic method for studying the hydrogen
bonding between complexes [10,11]. To elucidate the interac-
tion between CBZ and Cotran™ 9700, ATR-FTIR was used in
the following study. As can be seen from Fig. 2, there was no
difference in IR spectrum of the control (Fig. 2A) and the backing
Table 1 – Partition coefficients of CBZ from the backing films to the vehicle (n = 3, mean ± SD).
Backing film 9700 9718 9733 9723 69731
Partition coefficient 0.97 ± 0.25 0.14 ± 0.07 0.27 ± 0.08 0.32 ± 0.08 0.26 ± 0.06
Fig. 1 – The release profiles of CBZ patches with different
backing layers and the patches were stored for 0 day, 7
days and 15 days after preparation, respectively. Data were
presented as the mean ± SD (n = 3 or 4).
Fig. 2 – ATR-FTIR spectra of the backing film Cotran™ 9700
control (A) and after treated by CBZ solution (B).
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film Cotran™ 9700 was incubated in CBZ solution (Fig. 2B). It
was suggested that there was no hydrogen bonding between
CBZ and Cotran™ 9700. In Liu’s study, the drug has 4 H bond
acceptors and the polyurethane (shown in Fig. 3) in the struc-
ture of Cotran™ 9700 serves as H bond donor. However, CBZ
(shown in Fig. 4) has only 1 H bond acceptor. It can be in-
ferred that intermolecular hydrogen bonding was more difficult
to form between CBZ and Cotran™ 9700. Backing film Cotran™
9700 is a soft, conformable, melt-blown polyurethane, and is
nonwoven that has multi-directional stretch properties. It is
indicated that the backing film Cotran™ 9700 is porous and
the adsorption may exist in the porous structure. The adsorp-
tion of CBZ onto Cotran™ 9700 may be responsible for the less
cumulative release amount of transdermal patch.
4. Conclusion
The study investigated the effect of backing films on the release
of transdermal patch containing CBZ by in vitro release ex-
periments, partitioning experiments and ATR-FTIR methods.
It can be concluded that the adsorption of CBZ onto the
Cotran™ 9700 was responsible for the decreased release pro-
files of the CBZ transdermal patch. The cumulative release
amount further decreased after 7 days of storage and might
be because it took time to reach equilibrium of adsorption.The
adsorption between drug and backing film might have great
effect on the transdermal delivery and backing film should be
taken as an important factor in the formulation screening.
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Fig. 3 – The main-chain structure of polyurethane.
Fig. 4 – The chemical structure of cyclobenzaprine.
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